奥沙利铂+氟尿嘧啶治疗原发性肝癌的效果及对AFP、CA125、CA199、sFas、sFasL及VEGF表达的影响  

Effect of Oxaliplatin and Fluorouracil in the Treatment of Primary Liver Cancer and Influence for the Expression of AFP,CA125,CA199,sFas,sFasL and VEGF

作　　者：俞根 张世斌 李冬梅 江建军 陈剑 黄凌敏 YU Gen;ZHANG Shibin;LI Dongmei;JIANG Jianjun;CHEN Jian;HUANG Lingmin(Pingxiang Ganxi Cancer Hospital,Jiangxi Province,Pingxiang 337099,China;不详)

机构地区：[1]江西省萍乡赣西肿瘤医院,江西萍乡337099

出　　处：《中国医学创新》2022年第31期62-66,共5页Medical Innovation of China

基　　金：江西省卫生健康委科技计划项目(20197316)。

摘　　要：目的:探究奥沙利铂+氟尿嘧啶在原发性肝癌中的疗效及对甲胎蛋白(AFP)、糖类抗原-125(CA125)、糖类抗原-199(CA199)、可溶性脂肪酸合成酶(sFas)、可溶性脂肪酸合成酶配体(sFasL)及血管内皮生长因子(VEGF)表达的影响。方法:将2019年6月-2021年10月萍乡赣西肿瘤医院收治的80例原发性肝癌患者随机分为对照组(n=40)和观察组(n=40)。对照组采用顺铂+氟尿嘧啶进行治疗,观察组则采用奥沙利铂+氟尿嘧啶治疗。比较两组的治疗效果、各类不良反应发生情况、治疗前后的疾病相关血液指标[血清肿瘤标志物(AFP、CA125、CA199)及其他相关指标(sFas、sFasL及VEGF)]。结果:观察组的疾病控制率显著高于对照组,各类不良反应发生率均低于对照组,差异均有统计学意义(P<0.05)。治疗前,两组血清AFP、CA125、CA199、sFas、sFasL及VEGF比较,差异均无统计学意义(P>0.05)。治疗第1、2次后,观察组血清AFP、CA125、CA199、sFas、sFasL及VEGF均低于对照组,差异均有统计学意义(P<0.05)。结论:奥沙利铂+氟尿嘧啶在原发性肝癌中的疗效较好,安全性较高,可更为有效地控制疾病相关血液指标的表达。Objective:To investigate the efficacy of Oxaliplatin + Fluorouracil in primary liver cancer and its effect on the expression of alpha-fetoprotein (AFP),carbohydrate antigen-125 (CA125),carbohydrate antigen-199 (CA199),soluble fatty acid synthase (sFas),soluble fatty acid synthase ligand (sFasL) and vascular endothelial growth factor (VEGF).Method:A total of 80 patients with primary liver cancer who were admitted to Pingxiang Ganxi Cancer Hospital from June 2019 to October 2021 were randomly divided into control group (n=40) and observation group (n=40).The control group was treated with Cisplatin and Fluorouracil,the observation group was treated with Oxaliplatin and Fluorouracil.The treatment effect,various adverse reactions rates,before and after treatment disease-related blood indexes[serum tumor markers (AFP,CA125,CA199) and other relevant indexes (sFas,sFasL,VEGF)]were compared between the two groups.Result:The disease control rate of observation group was significantly higher than the rate of control group,the various adverse reactions rates were significantly lower than those of control group,the differences were statistically significant (P<0.05).The serum AFP,CA125,CA199,sFas,sFasL and VEGF of two groups before the treatment were compared,the differences were not statistically significant (P>0.05).After one and two times of treatment,the serum AFP,CA125,CA199,sFas,sFasL and VEGF in the observation group were lower than those in the of control group,the differences were statistically significant (P<0.05).Conclusion:The effect of Oxaliplatin and Fluorouracil in the patients with primary liver cancer is better,and its safety is higher,it can more effectively control the expression of disease-related blood indexes.

关 键 词：奥沙利铂 氟尿嘧啶 原发性肝癌 

分 类 号：R735.7[医药卫生—肿瘤]